Related Experiment Video
Updated: Nov 10, 2025
Purification of Human S100A12 and Its Ion-induced Oligomers for Immune Cell Stimulation
Published on: September 29, 2019
Up-to-date information on polymyxin B-immobilized fiber column direct hemoperfusion for septic shock
Chieko Mitaka1, Makio Kusaoi2, Izumi Kawagoe1
1Department of Anesthesiology and Pain Medicine, Juntendo University Faculty of Medicine, Tokyo, Japan.
Abstract:
Endotoxin adsorption therapy by polymyxin B-immobilized fiber column direct hemoperfusion (PMX-DHP) has been used for the treatment of septic shock patients. Endotoxin, an outer membrane component of Gram-negative bacteria, plays an important role in the pathogenesis of septic shock. Endotoxin triggers a signaling cascade for leukocytes, macrophage, and endothelial cells to secrete various mediators including cytokines and nitric oxide, leading to septic shock and multiple organ dysfunction syndrome. PMX-DHP directly adsorbed not only endotoxin but also monocytes and anandamide. It reduced blood levels of inflammatory cytokines such as interleukin (IL)-1, IL-6, tumor necrosis factor-alpha and IL-17A, adhesion molecules, plasminogen activator inhibitor 1, and high mobility group box-1. As a result, PMX-DHP increased blood pressure and reduced the dose of vasoactive-inotropic agents. PMX-DHP improved monocyte human leukocyte antigen-DR expression in patients with severe sepsis and septic shock. A post hoc analysis of EUPHRATES (Evaluating the Use of Polymyxin B Hemoperfusion in Randomized Controlled Trial of Adults Treated for Endotoxemia and Septic Shock) trial has shown that PMX-DHP significantly reduced 28-day mortality compared with the control group in septic shock patients with endotoxin activity assay level between 0.60 and 0.89. Longer duration of PMX-DHP may be another strategy to bring out the beneficial effects of PMX-DHP. Further studies are needed to confirm the efficacy of PMX-DHP treatment for septic shock.
Insights
Polymyxin B-immobilized fiber column direct hemoperfusion (PMX-DHP) effectively reduces endotoxin and inflammatory mediators in septic shock patients. This therapy improves hemodynamics and shows potential for reducing mortality in specific patient subgroups.
Area of Science:
- Critical Care Medicine
- Immunology
- Nephrology
Background:
- Septic shock is a life-threatening condition driven by endotoxin from Gram-negative bacteria.
- Endotoxin triggers inflammatory cascades leading to organ dysfunction.
- Current treatments for septic shock have limitations in addressing the underlying endotoxemia.
Purpose of the Study:
- To evaluate the efficacy of polymyxin B-immobilized fiber column direct hemoperfusion (PMX-DHP) in treating septic shock.
- To assess the impact of PMX-DHP on endotoxin levels, inflammatory mediators, and clinical outcomes.
Main Methods:
- Direct hemoperfusion using a polymyxin B-immobilized fiber column (PMX-DHP).
- Measurement of endotoxin, inflammatory cytokines (IL-1, IL-6, TNF-α, IL-17A), adhesion molecules, and monocyte human leukocyte antigen-DR expression.
- Analysis of hemodynamic parameters and mortality rates.
Main Results:
- PMX-DHP effectively adsorbed endotoxin, monocytes, and anandamide.
- Significant reduction in blood levels of key inflammatory cytokines and mediators was observed.
- Hemodynamic improvement, reduced need for vasoactive agents, and enhanced monocyte immune function were noted.
- A post hoc analysis of the EUPHRATES trial indicated reduced 28-day mortality in a specific endotoxin activity range.
Conclusions:
- PMX-DHP is a promising therapy for septic shock, directly targeting endotoxin and modulating the inflammatory response.
- The therapy demonstrates potential for improving clinical outcomes, including survival.
- Further research is warranted to optimize PMX-DHP duration and confirm its efficacy across diverse septic shock populations.
Related Concept Videos
01:25Extracorporeal Removal of Drugs: Hemoperfusion and Hemofiltration
01:30Extracorporeal Removal of Drugs: Peritoneal Dialysis and Hemodialysis